Active not recruitingPHASE2, PHASE3INTERVENTIONAL

A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME

At a glance

Status

Active not recruiting

Phase

PHASE2, PHASE3

Sponsor

EyeBiotech Ltd.

Enrolment target

984

Start

07 Aug 2024

Estimated completion

31 Dec 2027

Diabetic Macular Edema (DME)

What is this study about?

EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME)

In the first year, all 3 treatment groups will be treated every 4 weeks with either EYE103 or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm.

Approximately 960 participants will be entered in the study.

Who may be eligible?

Age 18 Years to any · Sex: ALL

Locations (183)

Scottsdale
Scottsdale, United States
Fayetteville, Arkansas
Fayetteville, United States
Springdale, Arkansas
Springdale, United States
Bakersfield, CA
Bakersfield, United States
Glendale, CA
Glendale, United States
Modesto, CA
Modesto, United States
Mountain View, CA
Mountain View, United States
Redlands, CA
Redlands, United States
Sacramento, CA
Sacramento, United States
Sacramento, CA
Sacramento, United States
Santa Ana
Santa Ana, United States
Colorado Springs, CO
Colorado Springs, United States

+171 more sites — see the official record for the full list.

How to find out more

Official trial record

Always speak to your GP or specialist before deciding to take part in a study.